You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,537,619


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,537,619
Title:Methods for treating osteoarthritis pain
Abstract: Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein.
Inventor(s): Turkel; Catherine C. (Newport Coast, CA), Jiang; Guang-Liang (Irvine, CA), DeGryse; Ronald E. (Laguna Beach, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/840,923
Patent Claims:1. A method for treating or alleviating osteoarthritis (OA)-associated pain in a patient in need thereof, the method comprising identifying an OA patient whose pain has been categorized as nociceptive pain, and locally administering a therapeutically effective amount of a clostridial derivative to an osteoarthritis-affected site of the OA patient whose pain has been categorized as nociceptive pain, thereby treating or alleviating the osteoarthritis-associated pain in the patient, wherein the therapeutically effective amount is from about 200 units to about 800 units, wherein the clostridial derivative is onabotulinumtoxinA, and wherein the identifying comprises providing the OA patient a plurality of questions relating to characteristics of OA-associated pain that the patient perceives, receiving numerical responses to the questions by the patient, calculating a score based on the numerical responses, comparing the score to a cut-off value to categorize the OA-associated pain; and identifying the patient whose pain has been categorized as nociceptive pain.

2. The method of claim 1, wherein the osteoarthritis-affected site is selected from the group consisting of a knee joint, a hip joint, a hand joint, a shoulder joint, an ankle joint, a foot joint, an elbow joint, a wrist joint, a sacroiliac joint, a spine joint, and combinations thereof.

3. The method of claim 1, wherein the administering is by intra-articular injection into a joint space.

4. The method of claim 1, wherein the therapeutically effective amount ranges from about 300 to about 500 units of onabotulinumtoxinA.

5. The method of claim 1, wherein the therapeutically effective amount is about 400 units.

6. The method of claim 1, wherein the patient's pain is categorized as nociceptive when the score is smaller than or equal to the cut-off value.

7. The method of claim 1, wherein two cut-off values are used for the categorization.

8. The method of claim 7, wherein the patient's pain is categorized as nociceptive when the score is smaller than or equal to a first cut-off value, the patient's pain is categorized as non-nociceptive when the score is greater than or equal to a second cut-off value, and the patient's pain is categorized as uncertain when the score is greater than the first cut-off value and smaller than the second cut-off value.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.